What is the present valuation and projected CAGR of the allogeneic cell therapy market?
The allogeneic cell therapy market size has grown rapidly in recent years. It will grow from $1.08 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to an increased focus on tailoring donor cell selection and genetic modifications, increased population, increase in the global burden of chronic diseases, increased awareness, and increase in the number of collaborations for biosimilar development.
The allogeneic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to the increasing need for advanced medical treatments, growing demand for novel allogeneic cell therapies, rising number of clinical trials, growing patient population contributions, and rising income levels. Major trends in the forecast period include technology advancements, partnerships, big companies collaborating with others, merger and acquisitions, new product launch.
Get Your Free Sample of The Global Allogeneic Cell Therapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp
What key drivers have fueled the allogeneic cell therapy market’s development over the years?
The increasing prevalence of chronic diseases is expected to drive the growth of the allogeneic cell therapy market. Chronic disease is a long-lasting condition that typically requires ongoing medical attention and can limit daily activities or quality of life. The prevalence of chronic disease is due to altered habits, inheritance, and exposure to chemicals, toxins, and pollutants in the air. Allogeneic cell therapy holds significant potential for treating a wide range of chronic diseases by utilizing healthy cells from a donor to repair, replace, or modulate the dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of people aged 50 and above who suffer from one or more chronic illnesses is expected to increase by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the increased prevalence of chronic diseases drives the growth of the allogeneic cell therapy market.
What is the segmentation for the allogeneic cell therapy market?
The allogeneic cell therapy market covered in this report is segmented –
1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders, Other Therapeutic Area
3) By End User: Hospitals, Specialty Clinics, Research Organizations
Subsegments:
1) By Stem Cell Therapies: Hematopoietic Stem Cell Therapy (Hematopoietic Stem Cells), Mesenchymal Stem Cell Therapy (MSC-Based Therapies), Induced Pluripotent Stem Cells (iPSC-Based Therapies), Neural Stem Cell Therapy, Other Stem Cell Therapies
2) By Non-Stem Cell Therapies: T-cell Therapies, Natural Killer (NK) Cell Therapies, Dendritic Cell Therapies, Other Non-Stem Cell Therapies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Who are the most influential companies in the allogeneic cell therapy market?
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG
What are the top industry trends projected to impact the allogeneic cell therapy market?
Major companies operating in the allogeneic cell therapy market are focusing on developing innovative solutions, such as cell processing platforms, to strengthen their position in the market. Cell processing platforms are systems and technologies used to prepare and manipulate cells for therapeutic applications, encompassing isolation, purification, expansion, modification, and quality control to ensure cells are suitable for clinical use. For instance, in March 2024, Getinge, a Sweden-based healthcare company, partnered with CellRev, a UK-based biotechnology company, to launch Livit ACE, a platform for continuous cell processing (Adherent Cell Expansion). This innovative platform integrates advanced automation and bioprocessing technologies, significantly enhancing the efficiency and scalability of cell production. Its unique features include state-of-the-art cell isolation and purification systems that ensure high cell purity and viability, robust expansion capabilities to produce large quantities of therapeutic cells, sophisticated genetic modification tools for precise cell engineering, and rigorous quality control measures to guarantee the safety and efficacy of the cell products.
What are the major regional insights for the allogeneic cell therapy market, and which region holds the top position?
North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Allogeneic Cell Therapy Market Report 2025 Offer?
The allogeneic cell therapy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Allogeneic cell therapy is a treatment in which cells are harvested from a donor and used to treat a different individual (the recipient). These therapies are designed to replace or repair damaged tissues, modulate immune responses, or treat diseases such as cancer, genetic disorders, and autoimmune conditions.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15976
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
